Abstract 489TiP
Background
Neoadjuvant anti-programmed cell death (ligand) 1 (PD[L]-1) inhibitors + CT have shown promising efficacy improvements compared with CT alone in pts with resectable NSCLC. Exploring neoadjuvant treatment containing novel agents that retain or improve efficacy and minimize safety risks may provide more clinical options for these pts. This phase 2 study aims to evaluate the preliminary efficacy, safety, and pharmacodynamics of TIS, an anti-PD-1 monoclonal antibody (mAb), as monotherapy and in multiple immunotherapy combinations +/- CT as neoadjuvant treatment in pts with resectable NSCLC.
Trial design
This phase 2 randomized, open-label, multicenter study (14 sites) will enroll approximately 120 treatment-naïve pts aged ≥18 years with EGFR mutation and ALK-rearrangement-negative stage II to IIIA NSCLC. The umbrella design allows for multiple investigational drugs, administered alone or in combination in a single disease population. Pts will be allocated to 1 of 2 substudies based on tumor cell PD-L1 expression. Sixty pts in Substudy 1 (PD-L1 ≥50%) will be randomized 1:1:1 to TIS monotherapy (Arm 1A), TIS + ociperlimab (anti-T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains mAb) (Arm 1B), or TIS + LBL-007 (anti-LAG-3 mAb) (Arm 1C). Sixty pts in Substudy 2 (PD-L1 <50%) will be randomized 1:2 to receive histology-specific (nonsquamous vs. squamous) CT in combination with TIS (Arm 2A) or TIS + LBL-007 (Arm 2C). All treatments will be administered on a 3-week cycle for 2–4 cycles followed by surgical resection and survival follow-up. The primary endpoint is major pathological response, per blinded independent pathology review (BIPR). Secondary endpoints include pathological complete response per BIPR, overall survival, event-free survival, and disease-free survival (both per investigator; RECIST v1.1), adverse events (per CTCAE v5.0), the proportion of pts who undergo surgical resection following treatment, and pharmacodynamic assessments of the investigational agents. Enrollment is ongoing.
Clinical trial identification
NCT05577702.
Legal entity responsible for the study
BeiGene.
Funding
BeiGene.
Disclosure
W. Yu: Financial Interests, Personal, Full or part-time Employment: BeiGene, BeiGene; Financial Interests, Personal, Stocks or ownership: BeiGene, BeiGene. J. Shi: Financial Interests, Personal, Full or part-time Employment: BeiGene; Financial Interests, Personal, Stocks or ownership: BeiGene. B. Wei: Financial Interests, Personal, Full or part-time Employment: BeiGene; Financial Interests, Personal, Stocks or ownership: BeiGene. W. Zheng: Financial Interests, Personal, Full or part-time Employment: BeiGene; Financial Interests, Personal, Stocks or ownership: BeiGene. Z. Shen: Financial Interests, Personal, Full or part-time Employment: BeiGene; Financial Interests, Personal, Stocks or ownership: BeiGene. All other authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract